| 19 March 2012 |
| 09:00 11:00 | | REGISTRATION
Registration |
| 11:00 13:00 | | Symposium 1: GENETIC REGULATION OF PITUITARY TUMOURIGENESIS
DEVELOPED WITH THE SOCIETY FOR ENDOCRINOLOGY'S PITUITARY SPECIAL INTEREST GROUP AND THE ASSOCIATION FOR MULTIPLE ENDOCRINE NEOPLASIA DISORDERS
QUEEN'S SUITE A
Chairs: R Fowkes (London) & H Chahal (London)
|
| 11:00 | S1.1 S1.1 | Genetic models of pituitary disease in MEN1
R Thakker (Oxford) |
| | | |
| 11:30 | S1.2 S1.2 | Modelling pituitary tumours in zebrafish
N-A Liu (Los Angeles, CA, USA) |
| | | |
| 12:00 | S1.3 S1.3 | Mouse model of craniopharyngioma
J Martinez-Barbera (London) |
| | | |
| 12:30 | S1.4 S1.4 | Molecular signatures of pituitary tumours
M Korbonits (London) |
| | | |
| 11:00 13:00 | | Symposium 2: ENDOPLASMIC RETICULUM STRESS IN METABOLIC DISEASE AND OBESITY
Stress caused by unfolded and misfolded proteins in the endoplasmic reticulum (so called "ER stress") intersects with metabolic disease at multiple levels
QUEEN'S SUITE B
Chairs: P Chapple (London) & E Harno (Manchester)
|
| 11:00 | S2.1 S2.1 | ER stress and metabolic regulation
D Ron (Cambridge) |
| | | |
| 11:30 | S2.2 S2.2 | ER stress, leptin signalling and obesity
U Ozcan (Boston, MA, USA) |
| | | |
| 12:00 | S2.3 S2.3 | Lipotoxic endoplasmic reticulum stress and pancreatic beta-cell demise in type 2 diabetes
M Cnop (Brussels, Belgium) |
| | | |
| 12:30 | S2.4 S2.4 | Patients with monogenic diabetes resulting from ER stress of the pancreatic beta-cell
A Hattersley (Plymouth) |
| | | |
| 11:00 13:00 | | Symposium 3: TESTOSTERONE IN MEN: HOW LOW CAN YOU GO?
DEVELOPED WITH THE SOCIETY FOR ENDOCRINOLOGY'S ANDROLOGY SPECIAL INTEREST GROUP AND THE KLINEFELTER'S SYNDROME ASSOCIATION
MAIN AUDITORIUM
Chairs: R Quinton (Newcastle) & A Theodoraki (London)
|
| 11:00 | S3.1 S3.1 | Is there a male menopause - lesson from the European Male Ageing Study
F Wu (Manchester) |
| | | |
| 11:30 | S3.2 S3.2 | Does testosterone treatment increase mortality in elderly men?
S Bhasin (Boston, MA, USA) |
| | | |
| 12:00 | S3.3 S3.3 | What is the best form of testosterone replacement?
P Bouloux (London) |
| | | |
| 12:30 | S3.4 S3.4 | Can testosterone therapy be stopped in some hypogonadal patients?
T Raivio (Helsinki, Finland) |
| | | |
| 13:00 13:30 | | LUNCH
HALL Q
|
| 13:30 15:30 | | Applied Physiology Workshop:
NANOMEDICINE
QUEEN'S SUITE B
Chairs: M Gurnell (Cambridge) & R Fowkes (London)
|
| 13:30 | AP1.1 AP1.1 | Magnetic nanoparticles for drug delivery
P Southern (London) |
| | | |
| 14:10 | AP1.2 AP1.2 | Nanoparticles as imaging agents
G Lanza (St Louis, MO, USA) |
| | | |
| 14:50 | AP1.3 AP1.3 | Nanomedicine in clinical diabetes
J Pickup (London) |
| | | |
| 13:30 15:30 | | Oral Communications 1: YOUNG ENDOCRINOLOGISTS' PRIZE SESSION
QUEEN'S SUITE A
Chairs: G Karsenty (New York, NY, USA) & J Newell-Price (Sheffield)
|
| 13:30 | OC1.1 OC1.1 | Functional characterisation and translational clinical applications of kisspeptin-10
J George (Edinburgh) |
| | | |
| 13:45 | OC1.2 OC1.2 | Structure-function analysis of calcium-sensing receptor (CaSR) mutations reveal clustering at calcium binding sites of the extracellular bilobed venus flytrap domain
F Hannan (Oxford) |
| | | |
| 14:00 | OC1.3 OC1.3 | Effect of selenium status on the skeleton in post-menopausal women: the OPUS study
A Gogakos (London) |
| | | |
| 14:15 | OC1.4 OC1.4 | The thyroid hormone receptor-coactivator interface mediates negative feedback regulation of the human pituitary-thyroid axis
C Moran (Cambridge) |
| | | |
| 14:30 | OC1.5 OC1.5 | Growth retardation and severe constipation due to the first human, dominant negative thyroid hormone receptor alpha mutation
N Schoenmakers (Cambridge) |
| | | |
| 14:45 | OC1.6 OC1.6 | A homozygous glutathione peroxidase 1 mutation, p.Arg130-Leu133del, in a patient with familial glucocorticoid deficiency
J Kowalczyk (London) |
| | | |
| 15:00 | OC1.7 OC1.7 | Progressive adrenal insufficiency and 46,XY DSD caused by two novel mutations in the cytochrome P450 side-chain cleavage (CYP11A1) gene
S Parajes (Birmingham) |
| | | |
| 15:15 | OC1.8 OC1.8 | Metastasis related methyltransferase 1 (Merm1)/WBSCR22 regulates glucocorticoid receptor (GR) function
M Jangani (Manchester) |
| | | |
| 13:30 15:30 | | Symposium 4: ADVANCES IN THE MANAGEMENT OF DIFFERENTIATED THYROID CANCER
Thyroid cancer management is evolving to reflect novel developments in imaging, cytology, molecular biology and the outcome of trials evaluating low versus high dose radioiodine therapy
MAIN AUDITORIUM
Chairs: K Boelaert (Birmingham) & P Newey (Oxford)
|
| 13:30 | S4.1 S4.1 | Can imaging predict malignancy in a thyroid nodule?
P Richards (London) |
| | | |
| 14:00 | S4.2 S4.2 | Predictive value of cytology and molecular markers in thyroid cancer
T Stephenson (Sheffield) |
| | | |
| 14:30 | S4.3 S4.3 | The place of radioiodine in the management of thyroid cancer
I Hay (Rochester, MN, USA) |
| | | |
| 15:00 | S4.4 S4.4 | Novel treatments - from PCR to patient
K Newbold (London) |
| | | |
| 15:30 16:00 | | TEA & COFFEE
HALL Q
|
| 16:00 18:00 | | Oral Communications 2: REPRODUCTION AND BONE
QUEEN'S SUITE B
Chairs: A McNeilly (Edinburgh) & E Vasilopoulou (Birmingham)
|
| 16:00 | OC2.1 OC2.1 | The expression of kisspeptin and kisspeptin receptor is altered in pre-eclampsia
P Williams (Nottingham) |
| | | |
| 16:15 | OC2.2 OC2.2 | Contrasting effects of kisspeptin-10 between men and women reveal sexual dimorphism in the hypothalamic regulation of human reproduction
C Jayasena (London) |
| | | |
| 16:30 | OC2.3 OC2.3 | Kissorphin, a hexapeptide derivative of kisspeptin, acts via neuropeptide FF receptors to inhibit cyclic adenosine monophosphate release but has no gonadotrophin-releasing hormone releasing activity
N Milton (London) |
| | | |
| 16:45 | OC2.4 OC2.4 | ERβ and GPR30 mediate distinct and opposite oestrogenic influences on microglial phagocytosis of apoptotic neuronal cells
S Vohra (London) |
| | | |
| 17:00 | OC2.5 OC2.5 | Nutrient regulation of growth factor signalling in human placenta
R Nadif (Manchester) |
| | | |
| 17:15 | OC2.6 OC2.6 | Identification of microRNAs involved in regulating growth factor signalling in the first trimester placenta
F Farrokhnia (Manchester) |
| | | |
| 17:30 | OC2.7 OC2.7 | Increased cardiovascular events in women with polycystic ovary syndrome: retrospective analysis of a large database
H Mani (Leicester) |
| | | |
| 17:45 | OC2.8 OC2.8 | A calcium-sensing receptor (CaSR) variant, Glu250Lys, present in familial hypocalciuric hypercalcaemia (FHH) and autosomal dominant hypocalcaemic hypercalciuria (ADHH) probands represents a functionally neutral polymorphism: lessons for CaSR mutational analysis
F Hannan (Oxford) |
| | | |
| 16:00 18:00 | | Symposium 5: SPRINT OR MARATHON? MUSCLING IN ON THE OLYMPICS
Muscle is recognised as important endocrine organ and target for the treatment of metabolic syndrome. This symposium will explore the breadth of our new understanding of basic metabolism and investigative clinical data that is currently emerging.
QUEEN'S SUITE A
Chairs: G Lavery (Birmingham) & N Morton (Edinburgh)
|
| 16:00 | S5.1 S5.1 | Muscles and their myokines
B Pedersen (Copenhagen, Denmark) |
| | | |
| 16:30 | S5.2 S5.2 | Exercise effects on fat metabolism and insulin sensitivity in human muscle
A Wagenmakers (Birmingham) |
| | | |
| 17:00 | S5.3 S5.3 | Novel signalling mechanisms controlling glycogen homeostasis in muscle
K Sakamoto (Dundee) |
| | | |
| 17:30 | S5.4 S5.4 | Mitochondrial dysfunction and muscle disease
S Rahman (London) |
| | | |
| 16:00 18:00 | | Clinical Management Workshop 1: THE LATE CONSEQUENCES OF CANCER THERAPY IN ADULTS
Two million people in the UK are living with or beyond cancer. Many are at risk of endocrinopathy
SUPPORTED BY CLINICAL ENDOCRINOLOGY, DEVELOPED WITH THE SOCIETY FOR ENDOCRINOLOGY'S LATE EFFECTS OF CANCER THERAPY SPECIAL INTEREST GROUP
MAIN AUDITORIUM
Chairs: M Druce (London) & A Kennedy (Birmingham)
|
| 16:00 | CM1.1 CM1.1 | The follow up of cancer survivors
D Greenfield (Sheffield) |
| | | |
| 16:30 | CM1.2 CM1.2 | The impact of cancer treatment on pituitary function
A Toogood (Birmingham) |
| | | |
| 17:00 | CM1.3 CM1.3 | The impact of cancer treatment on fertility and pregnancy
H Wallace (Edinburgh) |
| | | |
| 17:30 | CM1.4 CM1.4 | The late consequences of cancer therapy to the thyroid
G Brabant (Manchester) |
| | | |
| 18:00 18:10 | | BREAK
|
| 18:10 19:10 | | YOUNG ENDOCRINOLOGISTS' PRIZE LECTURES
MAIN AUDITORIUM
Chairs: K Chapman (Edinburgh) & A Grossman (London)
|
| 18:10 | YEP1.1 YEP1.1 | Challenging the dogma: Tissue specific regulation of insulin action
L Gathercole (Birmingham) |
| | | |
| 18:40 | YEP1.2 YEP1.2 | Quantifying in vivo extra-adrenal cortisol production and dysregulation in human metabolic disease
R Stimson (Edinburgh) |
| | | |
| 19:10 21:00 | | WELCOME RECEPTION
HALL Q
|
| 19:45 | | YOUNG ENDOCRINOLOGISTS' SOCIAL EVENING
HALL D
|
| 20 March 2012 |
| 07:00 07:15 | | BREAKFAST
MAIN AUDITORIUM FOYER & QUEEN'S SUITE FOYER
|
| 07:15 08:00 | | MEET THE EXPERT 1
Therapeutic management of adults with CAH
SUPPORTED BY CLINICAL ENDOCRINOLOGY
QUEEN'S SUITE A
Chair: S Ahmed (Glasgow)
Expert: W Arlt (Birmingham)
|
| 07:15 | MTE1 MTE1 | Therapeutic management of adults with CAH
W Arlt (Birmingham) |
| | | |
| 07:15 08:00 | | MEET THE EXPERT 2
Amiodarone
SUPPORTED BY CLINICAL ENDOCRINOLOGY
QUEEN'S SUITE B
Chair: A Weetman (Sheffield)
Expert: M Vanderpump (London)
|
| 07:15 | MTE2 MTE2 | Amiodarone
M Vanderpump (London) |
| | | |
| 07:15 08:00 | | MEET THE EXPERT 3
Preventing and managing long term complications of acromegaly
SUPPORTED BY CLINICAL ENDOCRINOLOGY
MAIN AUDITORIUM
Chair: R Murray (Leeds)
Expert: K Meeran (London)
|
| 07:15 | MTE3 MTE3 | Preventing and managing long term complications of acromegaly
K Meeran (London) |
| | | |
| 08:15 10:15 | | Symposium 6: INHIBITING STEROID ENZYMES TO TREAT COMMON DISEASE
Novel drugs targeting steroid synthesis and metabolism provide new avenues for treating human diseases
QUEEN'S SUITE A
Chairs: W Arlt (Birmingham) & S Alvarez-Madrazo (Glasgow)
|
| 08:15 | S6.1 S6.1 | Ageing gracefully - the role of 11beta-HSD1
M Cooper (Birmingham) |
| | | |
| 08:45 | S6.2 S6.2 | Old drugs for new targets - CYP11B2 inhibitors for hypertension
R Bernhardt (Saarbrucken, Germany) |
| | | |
| 09:15 | S6.3 S6.3 | Dual aromatase and steroid sulfatase inhibition in breast cancer
P Foster (Birmingham) |
| | | |
| 09:45 | S6.4 S6.4 | Potential prostate cancer drug target: bioactivation of androstanediol by conversion to dihydrotestosterone
E Wilson (Chapel Hill, NC, USA) |
| | | |
| 08:15 10:15 | | Oral Communications 3: OBESITY, THYROID AND ADDISON'S DISEASE
QUEEN'S SUITE B
Chairs: A Brooke (Exeter) & N Schoenmakers (Cambridge)
|
| 08:15 | OC3.1 OC3.1 | Metformin in obese children and adolescents (MOCA) trial
D Kendall (Manchester) |
| | | |
| 08:30 | OC3.2 OC3.2 | Post-prandial high fat intake leads to acute exposure to circulating endotoxin in type 2 diabetes mellitus subjects
A Harte (Coventry) |
| | | |
| 08:45 | OC3.3 OC3.3 | Risk of diabetes, cancer, large vessel disease and mortality in young women with polycystic ovary syndrome: a retrospective databased analysis
C Morgan (Cardiff) |
| | | |
| 09:00 | OC3.4 OC3.4 | Glucose absorption capacity of the mature adipose tissue is increased after Bardet-Biedl syndrome induced ciliary defect in adipocytes' precursors
V Marion (Strasbourg, France) |
| | | |
| 09:15 | OC3.5 OC3.5 | Steroidogenic function following B lymphocyte depletion therapy in new onset autoimmune Addison's disease
S Pearce (Newcastle) |
| | | |
| 09:30 | OC3.6 OC3.6 | GATA3 polymorphisms are associated with autoimmune Addison's disease
A Mitchell (Newcastle) |
| | | |
| 09:45 | OC3.7 OC3.7 | Subclinical hypothyroidism is associated with fatigue and impaired functional status in males in the Whickham 20-year follow up cohort
A Madathil (Newcastle) |
| | | |
| 10:00 | OC3.8 OC3.8 | Dietary factors augment the ability of the proto-oncogene PBF to induce goitrogenesis and hyperplasia in vivo
M Read (Birmingham) |
| | | |
| 08:15 10:15 | | Clinical Management Workshop 2: CONTROVERSIES IN AETIOLOGY AND MANAGEMENT OF OSTEOPOROSIS
SUPPORTED BY CLINICAL ENDOCRINOLOGY AND DEVELOPED WITH THE SOCIETY FOR ENDOCRINOLOGY'S BONE AND MINERAL SPECIAL INTEREST GROUP
MAIN AUDITORIUM
Chairs: S Orme (Leeds) & C Higham (Manchester)
|
| 08:15 | CM2.1 CM2.1 | Impact of lifestyle choices on skeletal health
N Peel (Sheffield) |
| | | |
| 08:45 | CM2.2 CM2.2 | Osteoporosis and metabolic bone disease in adolescence
N Bishop (Sheffield) |
| | | |
| 09:15 | CM2.3 CM2.3 | Complications of antiresorptive agents
B Abrahamsen (Copenhagen, Denmark) |
| | | |
| 09:45 | CM2.4 CM2.4 | New and emerging therapies for osteoporosis
R Eastell (Sheffield) |
| | | |
| 10:15 10:40 | | TEA & COFFEE
HALL Q
|
| 10:40 11:20 | | SOCIETY FOR ENDOCRINOLOGY DALE MEDAL LECTURE
MAIN AUDITORIUM
Chair: J Buckingham (London)
|
| 10:40 | PL1 PL1 | Estrogen receptor insensitivity: physiological and clinical consequences
K Korach (Durham, NC, USA) |
| | | |
| 11:20 12:00 | | SOCIETY FOR ENDOCRINOLOGY HOFFENBERG INTERNATIONAL MEDAL LECTURE
MAIN AUDITORIUM
Chair: G Williams (London)
|
| 11:20 | PL2 PL2 | Bone as endocrine organ
G Karsenty (New York, NY, USA) |
| | | |
| 12:00 14:00 | | LUNCH & POSTERS
HALL Q
|
| 14:00 16:00 | | Oral Communications 4: Steroids
QUEEN'S SUITE A
Chairs: R Bernhardt (Saarbrucken, Germany) & F McManus (Glasgow)
|
| 14:00 | OC4.1 OC4.1 | Increased 11β-hydroxysteroid dehydrogenase type 1 activity is associated with the adverse expression of glucocorticoid target genes in ageing human skin
A Tiganescu (Birmingham) |
| | | |
| 14:15 | OC4.2 OC4.2 | Age-dependent increase in the expression/activity of 11β-HSD1 in key metabolic tissues may underpin the ageing phenotype, notably sarcopenia
S Morgan (Birmingham) |
| | | |
| 14:30 | OC4.3 OC4.3 | A hypomorphic H6PD allele is sufficient to rescue the skeletal myopathy but not the lack of 11β-HSd type-1 mediated glucocorticoid regeneration phenotypes of H6PDKO mice
A Zielinska (Birmingham) |
| | | |
| 14:45 | OC4.4 OC4.4 | Broad phenotypic spectrum of 17a-hydroxylase deficiency: functional characterisation of 4 novel mutations in the CYP17A1 gene
J Idkowiak (Birmingham) |
| | | |
| 15:00 | OC4.5 OC4.5 | A novel repressor mechanism regulating fetal Leydig cell steroidogenesis, pertubation of which results in masculinization disorders
S van den Driesche (Edinburgh) |
| | | |
| 15:15 | OC4.6 OC4.6 | Fatty liver in a mouse model of congenital adrenal hyperplasia is driven by peroxisome proliferator-activated receptors
K McInnes (Edinburgh) |
| | | |
| 15:30 | OC4.7 OC4.7 | Glucocorticoids increase subcutaneous adipose tissue insulin sensitivity in vivo: a randomised double-blind, placebo controlled, cross over study
J Hazlehurst (Birmingham) |
| | | |
| 15:45 | OC4.8 OC4.8 | The role of a novel co-regulator in modifying the transcriptional activities of the glucocorticoid receptor
M Sadeq (Manchester) |
| | | |
| 14:00 16:00 | | Symposium 7: LATITUDE: ENDOCRINE CONSEQUENCES OF HUMAN MIGRATION
As humans have migrated towards the poles, a number of changes have occurred to our endocrine systems which have allowed us to adapt to our new environment, particularly daily and seasonal changes in light intensity and duration. In this symposium we will explore those endocrine systems most affected by latitudinal light levels and our adaptations to overcome these changes
MAIN AUDITORIUM
Chairs: D Renshaw (London) & A McNeilly (Edinburgh)
|
| 14:00 | S7.1 S7.1 | The origins and evolution of lactase persistence
M Thomas (London) |
| | | |
| 14:30 | S7.2 S7.2 | Melatonin, light and sleep in the Antartic
J Arendt (Guildford) |
| | | |
| 15:00 | S7.3 S7.3 | Cortisol and mood - coping with seasons
A Clow (London) |
| | | |
| 15:30 | S7.4 S7.4 | Resurgence of vitamin D deficiency rickets in the UK
Z Mughal (Manchester) |
| | | |
| 14:00 16:00 | | Young Endocrinologists' Symposium: OBTAINING FUNDING AND NETWORKING FOR YOUNG ENDOCRINOLOGISTS
QUEEN'S SUITE B
Chairs: V Cabrera-Sharp (London) & S Mirczuk (London)
|
| 14:00 | YE1.1 YE1.1 | Obtaining fellowship funding and networking
K Forbes (Manchester) |
| | | |
| 14:30 | YE1.2 YE1.2 | Pathways in clinical academia, fellowships and networking
A Tahrani (Birmingham) |
| | | |
| 15:00 | YE1.3 YE1.3 | Career opportunities in the States
I Thompson (Boston, MA, USA) |
| | | |
| 15:30 | YE1.4 YE1.4 | Trials and tribulations of the university lecturer
R Fowkes (London) |
| | | |
| 16:00 16:30 | | TEA & COFFEE
HALL Q
|
| 16:30 17:30 | | Clinical Debate:
THIS HOUSE BELIEVES THAT ALL ADRENAL PATIENTS WITH INCIDENTALOMA WHO FAIL TO SUPPRESS CORTISOL AFTER DEXAMETHASONE SHOULD HAVE AN ADRENALECTOMY
MAIN AUDITORIUM
Chair: S Shalet (Manchester)
For: B Atkinson (Belfast) Against: P Stewart (Birmingham)
|
| 16:30 17:15 | | MEET THE EXPERT 1 - REPEAT
Therapeutic management of adults with CAH
SUPPORTED BY CLINICAL ENDOCRINOLOGY
HALL D
Chair: S Ahmed (Glasgow)
Expert: W Arlt (Birmingham)
|
| 16:30 | MTE1 MTE1 | Therapeutic management of adults with CAH
W Arlt (Birmingham) |
| | | |
| 16:30 18:30 | | Oral Communications 5: GROWTH, TUMOURS AND PITUITARY
QUEEN'S SUITE A
Chairs: J Webster (Sheffield) & V Smith (Birmingham)
|
| 16:30 | OC5.1 OC5.1 | Human growth is regulated by an ubiquitination pathway including CUL7, OBSL1 and CCDC8
D Hanson (Manchester) |
| | | |
| 16:45 | OC5.2 OC5.2 | A network analysis of gene expression through childhood highlights changes related to age and growth
A Stevens (Manchester) |
| | | |
| 17:00 | OC5.3 OC5.3 | Long term experience of 131I-MIBG therapy in the treatment of neuroendocrine tumours: has it improved survival and what are the long term sequelae?
C Sze (London) |
| | | |
| 17:15 | OC5.4 OC5.4 | Steroid metabolomics in adrenocortical carcinoma reveal mitotane as an inducer of CYP3A4 and an inhibitor of 5alpha-reductase activity with major implications for drug metabolism and hydrocortisone replacement
A Taylor (Birmingham) |
| | | |
| 17:30 | OC5.5 OC5.5 | Role of the hypoxic signalling pathways in the histopathological prediction of malignancy in phaeochromocytomas and paragangliomas
D Pinato (London) |
| | | |
| 17:45 | OC5.6 OC5.6 | SUMOylation genes in pituitary gonadotrophs: wrestling with GnRH signalling
S Mirczuk (London) |
| | | |
| 18:00 | OC5.7 OC5.7 | The role of the familialpituitary adenoma gene, AIP, in the proliferative and invasive activity of a malignant pancreatic cell line
J Saleh (London) |
| | | |
| 18:15 | OC5.8 OC5.8 | Control of GH and IGF1 in acromegaly in the UK: responses to medical treatment
T Howlett (Leicester) |
| | | |
| 16:30 18:30 | | Symposium 8: SMALL MOLECULES, BIG EFFECTS: THE EMERGING ROLE FOR MICRO RNAS
MicroRNAs have emerged in recent years as key regulators in cancer and endocrine disease. They dramatically modify gene expression at the post-transcriptional stage
QUEEN'S SUITE B
Chairs: M Westwood (Manchester) & S Wood (Glasgow)
|
| 16:30 | S8.1 S8.1 | MicroRNA: an introduction
M Bushall (Leicester) |
| | | |
| 17:00 | S8.2 S8.2 | MicroRNA regulation of the IGF axis
K Forbes (Manchester) |
| | | |
| 17:30 | S8.3 S8.3 | MicroRNA and the beta-cell
M Poy (Berlin, Germany) |
| | | |
| 18:00 | S8.4 S8.4 | MicroRNA in the diagnosis and therapy of endcorine cancers
P Igaz (Budapest, Hungary) |
| | | |
| 17:15 18:00 | | MEET THE EXPERT 2 - REPEAT
Amiodarone
SUPPORTED BY CLINICAL ENDOCRINOLOGY
HALL D
Chair: A Weetman (Sheffield)
Expert: M Vanderpump (London)
|
| 17:15 | MTE2 MTE2 | Amiodarone
M Vanderpump (London) |
| | | |
| 18:40 19:10 | | SOCIETY FOR ENDOCRINOLOGY TRANSATLANTIC MEDAL
MAIN AUDITORIUM
Chair: P Stewart (Birmingham)
|
| 18:40 | PL3 PL3 | Metabolism to epigenetics: the circadian clock link
P Sassone-Corsi (Irvine, CA, USA) |
| | | |
| 19:40 00:00 | | CONFERENCE DINNER
ROYAL HALL
|
| 21 March 2012 |
| 07:00 07:15 | | BREAKFAST
QUEEN'S SUITE FOYER
|
| 07:15 08:00 | | MEET THE EXPERT 4
Management of persistent TSH elevation in hypothyroid patients
SUPPORTED BY CLINICAL ENDOCRINOLOGY AND THE BRITISH THYROID FOUNDATION
QUEEN'S SUITE A
Chair: J Wass (Oxford)
Expert: A Allahabadia (Sheffield)
|
| 07:15 | MTE4 MTE4 | Management of persistent TSH elevation in hypothyroid patients
A Allahabadia (Sheffield) |
| | | |
| 07:15 08:00 | | MEET THE EXPERT 5
The surgical approaches to MEN1 - what the endocrinologist needs to know
SUPPORTED BY CLINICAL ENDOCRINOLOGY
QUEEN'S SUITE B
Chair: S Ball (Newcastle)
Expert: B Harrison (Sheffield)
|
| 07:15 | MTE5 MTE5 | The surgical approaches to MEN1 - what the endocrinologist needs to know
B Harrison (Sheffield) |
| | | |
| 08:00 08:10 | | BREAKFAST
MAIN AUDITORIUM FOYER
|
| 08:10 08:55 | | SOCIETY FOR ENDOCRINOLOGY ANNUAL GENERAL MEETING
MAIN AUDITORIUM
|
| 09:00 11:00 | | Symposium 9: DEVELOPMENTAL PROGRAMMING OF ENDOCRINE DISEASE
It’s not what I eat, it’s what my mother ate. Can maternal lifestyle or nutrition programme life-long metabolic and endocrine problems in their offspring.
QUEEN'S SUITE A
Chairs: A Fowden (Cambridge) & O Brand (Oxford)
|
| 09:00 | S9.1 S9.1 | Developmental programming of type 2 diabetes
S Ozanne (Cambridge) |
| | | |
| 09:30 | S9.2 S9.2 | Neuroendocrine origins of obesity
S Bouret (Los Angeles, CA, USA) |
| | | |
| 10:00 | S9.3 S9.3 | The foetus or the placenta? Targets of glucorticoid programming
M Holmes (Edinburgh) |
| | | |
| 10:30 | S9.4 S9.4 | Obesity in pregnancy: implications for the next generation
S Ford (Laramie, WY, USA) |
| | | |
| 09:00 11:00 | | Symposium 10:
CURRENT CONCEPTS AND MANAGEMENT OF PHAEOCHROMOCYTOMA
SUPPORTED BY THE ASSOCIATION FOR MULTIPLE ENDOCRINE NEOPLASIA DISORDERS
MAIN AUDITORIUM
Chairs: J Connell (Dundee) & U Srirangalingam (London)
|
| 09:00 | S10.1 S10.1 | Genetics and epidemiology
E Maher (Birmingham) |
| | | |
| 09:30 | S10.2 S10.2 | Molecular mechanisms of phaeochromocytoma and tumorigenesis
P Dahia (San Antonio, TX, USA) |
| | | |
| 10:00 | S10.3 S10.3 | Laboratory assessment and diagnostic imaging
H Timmers (Nijmegen, The Netherlands) |
| | | |
| 10:30 | S10.4 S10.4 | Novel therapies for malignant phaeochromocytomas and paragangliomas
P-F Plouin (Paris, France) |
| | | |
| 09:00 11:00 | | Nurses' Session 1:
THYROID EYE DISEASE
SUPPORTED BY THE THYROID EYE DISEASE CHARITABLE TRUST
QUEEN'S SUITE B
Chairs: D Wright (Bradford) & N Ellis (Bradford)
|
| 09:00 | N1.1 N1.1 | Thyroid Eye Disease - presentation and treatment
R Ajjan (Leeds) |
| | | |
| 10:00 | N1.2 N1.2 | Thyroid Eye Disease
M Morris (Newcastle) |
| | | |
| 10:30 | N1.3 N1.3 | Thyroid Eye Disease
J McLaren (Thyroid Eye Disease Charitable Trust) |
| | | |
| 11:00 11:30 | | TEA & COFFEE
|
| 11:30 12:00 | | SOCIETY FOR ENDOCRINOLOGY EUROPEAN MEDAL LECTURE
MAIN AUDITORIUM
Chair: M Korbonits (London)
|
| 11:30 | PL4 PL4 | GLP-1 therapy of type 2 diabetes - current status
J Juul-Holst (Copenhagen, Denmark) |
| | | |
| 12:00 12:30 | | SOCIETY FOR ENDOCRINOLOGY JUBILEE MEDAL LECTURE
MAIN AUDITORIUM
Chair: G Williams (London)
|
| 12:00 | PL5 PL5 | Acromegaly - improving outcomes
M Sheppard (Birmingham) |
| | | |
| 12:30 13:45 | | LUNCH
HALL Q
|
| 13:45 15:45 | | Symposium 11: NOVEL LESSONS FROM MINERALOCORTICOID EXCESS
Recent breakthroughs from the genetics of mineralocorticoid hypertension
QUEEN'S SUITE A
Chairs: E Davies (Glasgow) & E Nogueira (Birmingham)
|
| 13:45 | S11.1 S11.1 | A difficult TASK: murine models of mineralocorticoid excess
R Warth (Regensburg, Germany) |
| | | |
| 14:15 | S11.2 S11.2 | Human potassium channel mutations and mineralocorticoid hypertension
M Zennaro (Paris, France) |
| | | |
| 14:45 | S11.3 S11.3 | Long term consequences of primary hyperaldosteronism
M Reincke (Munich, Germany) |
| | | |
| 15:15 | S11.4 S11.4 | Therapeutic options for mineralocorticoid hypertension
J Connell (Dundee) |
| | | |
| 13:45 15:45 | | Symposium 12: MEDULLARY THYROID CANCER
Emerging knowledge of the molecular mechanisms in medullary carcinoma of the thyroid is improving our understanding of this condition, which is now impacting on therapy
MAIN AUDITORIUM
Chairs: D Bassett (London) & V Smith (Birmingham)
|
| 13:45 | S12.1 S12.1 | Molecular pathogenesis of MTC
M Santoro (Naples, Italy) |
| | | |
| 14:15 | S12.2 S12.2 | RAS mutations in sporadic MTC
V Leite (Lisbon, Portugal) |
| | | |
| 14:45 | S12.3 S12.3 | The diagnosis and management of MTC
T Kurzawinski (London) |
| | | |
| 15:15 | S12.4 S12.4 | Novel targeted therapies for MTC
M Schlumberger (Paris, France) |
| | | |
| 13:45 15:45 | | Nurses' Session 2:
ADDISON'S/PHAEOCHROMOCYTOMAS/CONN'S SYNDROME
QUEEN'S SUITE B
Chairs: S Gorick (Norwich) & V Kieffer (Leicester)
|
| 13:45 | N2.1 N2.1 | Conn's and phaeochromocytoma
S Myint (Norwich) |
| | | |
| 14:15 | N2.2 N2.2 | Nursing case study on phaeochromocytoma
P Yeoh (London) |
| | | |
| 14:30 | N2.3 N2.3 | Introduction to Addison's
T Howlett (Leicester) |
| | | |
| 15:00 | N2.4 N2.4 | Day-to-day practice on management of steroid replacement
V Thornton-Jones (Oxford) |
| | | |
| 15:15 | N2.5 N2.5 | Living with Addison's
H Dawson-Smith (Addison's Disease Self-Help Group) |
| | | |
| 13:45 14:30 | | MEET THE EXPERT 8
Optogenetics: controlling cells with light
HALL D
Chair: R Andrew (Edinburgh)
Expert: R Allemann (Cardiff)
|
| 13:45 | MTE8 MTE8 | Optogenetics: controlling cells with light
R Allemann (Cardiff) |
| | | |
| 14:45 15:30 | | MEET THE EXPERT 9
All you need to know about CHIP-sequencing
HALL D
Chair: C McCabe (Birmingham)
Expert: J Carroll (Cambridge)
|
| 14:45 | MTE9 MTE9 | All you need to know about CHIP-sequencing
J Carroll (Cambridge) |
| | | |
| 15:45 16:15 | | TEA & COFFEE
HALL Q
|
| 16:15 16:45 | | AWARDS CEREMONY
MAIN AUDITORIUM
Chair: J Buckingham (London)
|
| 17:15 17:45 | | SOCIETY FOR ENDOCRINOLOGY MEDAL LECTURE
MAIN AUDITORIUM
Chair: J Buckingham (London)
|
| 17:15 | PL7 PL7 | Genetic, molecular and physiological mechanisms involved in human obesity
S Farooqi (Cambridge) |
| | | |
| 18:00 18:45 | | BRITISH THYROID ASSOCIATION PITT-RIVERS LECTURE
MAIN AUDITORIUM
Chair: G Williams (London)
|
| 16:45 | PL6 PL6 | The thyroid - too much and too little across the ages
J Franklyn (Birmingham) |
| | | |
| 18:00 19:30 | | Otsuka satellite symposium
Chair: P Bouloux (London)
|
| 18:00 | OS1 OS1 | Hyponatraemia in neurosurgical patients: insights and implications
|
| | | |
| 18:45 | OS2 OS2 | Accelerating post-aneurysm recovery by correcting hypotraemia
|
| | | |
| 18:00 19:30 | | How do we balance a 21st century medicine with a 21st century economy?
|
| 22 March 2012 |
| 07:00 07:15 | | BREAKFAST
QUEEN'S SUITE FOYER
|
| 07:30 08:15 | | MEET THE EXPERT 6
Prioritising therapy in neuroendocrine tumours
SUPPORTED BY CLINICAL ENDOCRINOLOGY
QUEEN'S SUITE A
Chair: S Aylwin (London)
Expert: C Toumpanakis (London)
|
| 07:30 | MTE6 MTE6 | Prioritising therapy in neuroendocrine tumours
C Toumpanakis (London) |
| | | |
| 07:30 08:15 | | MEET THE EXPERT 7
Regulating periods and optimising fertility in PCOS
SUPPORTED BY CLINICAL ENDOCRINOLOGY
QUEEN'S SUITE B
Chair: H Randeva (Warwick)
Expert: C Duncan (Edinburgh)
|
| 07:30 | MTE7 MTE7 | Regulating periods and optimising fertility in PCOS
C Duncan (Edinburgh) |
| | | |
| 08:30 09:00 | | CLINICAL ENDOCRINOLOGY TRUST MEDAL LECTURE
Developing growth hormone agonists and antagonists for the clinic
SUPPORTED BY CLINICAL ENDOCRINOLOGY TRUST
MAIN AUDITORIUM
Chair: J Bevan (Aberdeen)
|
| 08:30 | PL8 PL8 | Developing growth hormone agonists and antagonists for the clinic
R Ross (Sheffield) |
| | | |
| 09:00 09:30 | | CLINICAL ENDOCRINOLOGY TRUST VISITING PROFESSOR LECTURE
Long-term outcome and quality of life in patients with disorders of sex development
SUPPORTED BY CLINICAL ENDOCRINOLOGY TRUST
MAIN AUDITORIUM
Chair: J Connell (Dundee)
|
| 09:00 | PL9 PL9 | Long-term outcome and quality of life in patients with disorders of sex development
B Mendoca (Sao Paulo, Brazil) |
| | | |
| 09:30 10:00 | | Funding opportunities: NIHR/MRC Efficacy and Mechanisms Evaluations (EME) Board
MAIN AUDITORIUM
|
| 09:30 | FO1.1 FO1.1 | Opportunities in translational research - the NIHR/MRC Efficacy and Mechanisms Evaluations (EME) Board
R Thakker (London) |
| | | |
| 09:45 | FO1.2 FO1.2 | NIHR research networks: an update
J Wilding (Liverpool) |
| | | |
| 10:00 10:30 | | TEA & COFFEE
HALL Q
|
| 10:30 13:00 | | SENIOR ENDOCRINOLOGISTS' SESSION
HALL D
|
| 10:30 | SE1.1 SE1.1 | Seeing the light
B Cooke (Harpenden) |
| | | |
| 10:55 | SE1.2 SE1.2 | It's time to identify the hormone that maintains bodty fat content
G Hervey (Leeds) |
| | | |
| 11:20 | SE1.3 SE1.3 | UK stance on adult GH replacment maintains our isolation from Europe
S Shalet (Manchester) |
| | | |
| 11:45 | SE1.4 SE1.4 | Assisted conception and developing low cost version for the developing world
I Cooke (Sheffield) |
| | | |
| 12:10 | SE1.5 SE1.5 | Tales from an arthritic endocrinologist - why does the endocrine dog not bark in the cytokine night?
C Edwards (London) |
| | | |
| 12:35 | SE1.6 SE1.6 | Psychopathology of false conviction
D Anderson (Montecastello di Vibio, Italy) |
| | | |
| 10:30 12:30 | | Clinical Management Workshop 3: ADVANCES IN ASSESSMENT AND MANAGEMENT OF INFERTILITY
What the endocrinologist needs to know
SUPPORTED BY CLINICAL ENDOCRINOLOGY
QUEEN'S SUITE A
Chairs: W Dhillo (London) & J George (Edinburgh)
|
| 10:30 | CM3.1 CM3.1 | Novel mutations causing infertility
N Pitteloud (Lausanne, Switzerland) |
| | | |
| 11:00 | CM3.2 CM3.2 | Semen analysis: what does it mean and can we improve it?
C Barratt (Dundee) |
| | | |
| 11:30 | CM3.3 CM3.3 | How can we predict ovarian reserve and how useful is this?
F Broekmans (Utrecht, The Netherlands) |
| | | |
| 12:30 | CM3.4 CM3.4 | The endocrine basis of what we do in the IVF clinic
G Trew (London) |
| | | |
| 10:30 12:30 | | Clinical Management Workshop 4: HOW DO I APPROACH...
Real world approaches to clinical dilemmas
SUPPORTED BY CLINICAL ENDOCRINOLOGY
MAIN AUDITORIUM
Chairs: J Bevan (Aberdeen) & A Paisley (Manchester)
|
| 10:30 | CM4.1 CM4.1 | Drug-induced hyperprolactinaemia
T Kearney (Salford) |
| | | |
| 10:50 | CM4.2 CM4.2 | Endocrine assessment in HIV/AIDS
A Wren (London) |
| | | |
| 11:10 | CM4.3 CM4.3 | Neuroendocrine assessment in morbid obesity
J Wilding (Liverpool) |
| | | |
| 11:30 | CM4.4 CM4.4 | Endocrine evaluation in a patient with coeliac disease
S Pearce (Newcastle) |
| | | |
| 11:50 | CM4.5 CM4.5 | Hypogonadism in a man with cancer of the prostate
H Jones (Sheffield) |
| | | |
| 12:10 | CM4.6 CM4.6 | Endocrine evaluation in a patient with iron overload
J Kirk (Birmingham) |
| | | |
| 12:30 13:15 | | MEET THE EXPERT 5 - REPEAT
The surgical approaches to MEN1 - what the endocrinologist needs to know
SUPPORTED BY CLINICAL ENDOCRINOLOGY
MAIN AUDITORIUM
Chair: S Ball (Newcastle)
Expert: B Harrison (Sheffield)
|
| 12:30 | MTE5 MTE5 | The surgical approaches to MEN1 - what the endocrinologist needs to know
B Harrison (Sheffield) |
| | | |
| 12:30 13:15 | | MEET THE EXPERT 4 - REPEAT
Management of persistent TSH elevation in hypothyroid patients
SUPPORTED BY CLINICAL ENDOCRINOLOGY AND THE BRITISH THYROID FOUNDATION
QUEEN'S SUITE B
Chair: J Wass (Oxford)
Expert: A Allahabadia (Sheffield)
|
| 12:30 | MTE4 MTE4 | Management of persistent TSH elevation in hypothyroid patients
A Allahabadia (Sheffield) |
| | | |
| 12:30 13:15 | | MEET THE EXPERT 3 - REPEAT
Preventing and managing long term complications of acromegaly
SUPPORTED BY CLINICAL ENDOCRINOLOGY
QUEEN'S SUITE A
Chair: R Murray (Leeds)
Expert: K Meeran (London)
|
| 12:30 | MTE3 MTE3 | Preventing and managing long term complications of acromegaly
K Meeran (London) |
| | | |
| 13:15 14:00 | | MEET THE EXPERT 7 - REPEAT
Regulating periods and optimising fertility in PCOS
SUPPORTED BY CLINICAL ENDOCRINOLOGY
QUEEN'S SUITE B
Chair: H Randeva (Warwick)
Expert: C Duncan (Edinburgh)
|
| 13:15 | MTE7 MTE7 | Regulating periods and optimising fertility in PCOS
C Duncan (Edinburgh) |
| | | |
| 13:15 14:00 | | MEET THE EXPERT 6 - REPEAT
SUPPORTED BY CLINICAL ENDOCRINOLOGY
QUEEN'S SUITE A
Chair: S Aylwin (London)
Expert: C Toumpanakis (London)
|
| 13:15 | MTE6 MTE6 | Prioritising therapy in neuroendocrine tumours
C Toumpanakis (London) |
| | | |